Emepronium

Summary

Emepronium (CHEMBL2110805) is an approved small molecule (ATC N05CX05); indicated across 2 conditions.

At a glance

• Status: Approved (max clinical phase 4)
• Modality: Small molecule
• ATC class: N05CX05 (+1 more)
• Indications: 2 conditions
• Chemistry: 282.4 Da · C20H28N+

Identifiers

Drug identity and classification

Field	Value
ChEMBL ID	CHEMBL2110805
Name	Emepronium
Type	Small molecule
Max phase	4
FDA approved	no
PubChem CID	34055
ATC	N05CX05, G04BD01
Molecular formula	C20H28N+
Molecular weight	282.4
InChIKey	JEJBJBKVPOWOQK-UHFFFAOYSA-N

SMILES: CC[N+](C)(C)C(C)CC(C1=CC=CC=C1)C2=CC=CC=C2

IUPAC name: 4,4-diphenylbutan-2-yl-ethyl-dimethylazanium

Also known as: Emepronium, Emepronium cation, Emepronium ion, EMEPRONIUM

Parent form; salt/anhydrous children: CHEMBL2106122

Patent coverage: 155 distinct patent families (662 SureChEMBL compound mentions), from 1 matched compound structure(s). Mentions count patents naming the compound (not distinct inventions), so promiscuous / reference molecules inflate the mention figure — families are the dedup metric.

Targets

Targets

No target linkage available.

Bioactivity

No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).

Target pathways

No target-pathway data for this drug (no mapped target genes).

Indications & clinical

Indications

2 indication records carry no mapped disease name (EFO/MeSH-only); none shown.

Clinical trials

Total trials: 0.

Clinical evidence (CIViC)

No CIViC predictive evidence (expected for non-precision-medicine drugs).

Pharmacology

Pharmacogenomics

No PharmGKB pharmacogenomic data curated for this drug.

Related molecules

Related molecules

No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).